Drug Discovery World

MAY 6, 2024

During the period 2016-2021, the Brazilian, Chinese and Indian markets grew by 11.7%, 6.7% respectively compared to an average market growth of 5.8% for the top five European Union markets and 5.6% for the US market 2. So, in this way there is a cross fertilisation from the bigger companies to newer ones.

Drugs 59

Drugs Life Science Gene Editing Gene 59

pharmaphorum

SEPTEMBER 29, 2020

The industry is asking itself how to stay innovative, how to develop and bring to market higher quality therapies to patients – and how to do this faster and more efficiently. It enables the companies to work closely together, throughout the continuum of research, development and commercialisation. A diversity of collaboration types.

Research 117

Research Gene Editing Gene Development 117

Pharmaceutical Technology

MAY 26, 2023

The British company’s expanded facilities boasts of 11 suites, including two class B filling suites with class A filling cabinets, warehousing and quality control laboratory capability. One big pharma company has already given the seal of approval with a successful customer quality audit.

DNA 130

DNA Manufacturing Gene Therapy Gene 130

XTalks

DECEMBER 29, 2022

This highlights potentially new marketing trends that life science companies may have to start looking into if they haven’t already. In 2022 alone, the US regulator approved four new gene therapies, showing the high interest in getting these therapies to market. 4. Social Media Marketing.

Life Science 52

Life Science Gene Therapy Gene Manufacturing 52

Drug Discovery World

OCTOBER 16, 2023

Dr Tralau-Stewart says: “Indeed, many academic institutions have established new ways of supporting the discovery pipeline, providing tech transfer offices to support licensing, and entrepreneurship and start-up support through fundraising, accelerators, and incubators.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

Drug Discovery World

OCTOBER 7, 2022

It is about going faster in progressing our innovation to market, taking things further along the value chain as we de-risk the early science. Our ability to invest in, or partner to access, new technologies and capabilities is also enhanced within the new structure, enabling us to move faster to progress our innovations to market. .

HR 52

HR Research Drugs Development 52